Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Novartis Gene Therapies Med Info (US, Latin America, Canada) +1-833-828-3947
medinfo.gtx@novartis.com


Novartis Gene Therapies Med Info (Europe, Middle East, Africa, Asia-Pacific) +353 (1) 566-2364
medinfoemea.gtx@novartis.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Back

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

Recruiting

Open to: ALL

Age: All

Newcastle Upon Tyne London

Medical Conditions

Muscular Atrophy
Muscular Atrophy, Spinal
Atrophy

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a global, prospective, multi-center study that is designed to assess the long-term safety and efficacy of OAV101 in patients who participated in an OAV101 clinical trial. The assessments of safety and efficacy in Study COAV101A12308 will continue for 15 years from the date of OAV101 administration in the previous clinical trial.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2022 Oct 2039

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.

Intervention Arm Group : Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Novartis Investigative Site
    Newcastle Upon Tyne
    NE1 4LP
  • Novartis Investigative Site
    London
    WC1N 3JH

Novartis Gene Therapies Med Info (Europe, Middle East, Africa, Asia-Pacific) +353 (1) 566-2364
medinfoemea.gtx@novartis.com


Novartis Gene Therapies Med Info (US, Latin America, Canada) +1-833-828-3947
medinfo.gtx@novartis.com



The study is sponsored by Novartis Pharmaceuticals



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05335876
Last updated 22 May 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top